1. Scrip
  2. >>Business

Zydus Cadila Readies Injectables Push Amid Tepid US Growth Outlook

COVID-19 Vaccine Found Safe In Phase I Trials

 
• By Vibha Ravi

Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.

Guidance word in red keyboard buttons
Zydus Cadila Forecasts Tepid Growth In The US • Source: Shutterstock

After an 8% fall in first quarter US sales over the previous quarter led by the impact of COVID-19 and the seasonal drop in sales of oseltamivir, Zydus Cadila expects “mid-to-high” single digit growth in its biggest market during financial year 2021. Prospects for India sales, which also dipped during Q1, are seen improving too.

As one of the main contributors to US revenue, Asacol -HD (mesalamine) delayed release tablets for treatment of mild to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.